30 closest matches · ranked by relevance
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 percentage of participants
Advanced Solid Tumors
Primary: Overall Response Rate (ORR) — 5.6; 0.0; 11.3; 14.3 percentage of participants
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Solid Tumor, Adult
Primary: Number of Participants With Adverse Events (AEs), and Serious Adverse Events (SAEs). — 11; 3 Participants
Solid Tumor
Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Advanced Solid Tumors
Primary: Pharmacokinetic Analysis: Dose-adjusted AUC(0-∞) — 288.55; 105.8 μg·h/L/mg
Solid Tumors
Primary: Dose-escalation Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0 Participants
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 180 Milligram (mg)
Advanced Malignant Solid Neoplasm
Primary: Number of Participants With an Objective Response — 0; 0; 0; 0 Participants
Carcinoid Tumor · Metastatic Carcinoid Tumor · Neuroendocrine Neoplasm
Primary: PFS — 11 months
Cancer
Primary: Response and Progression Will be Evaluated in This Study Using the New International Criteria Proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)…
Neoplasms
Primary: Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Chemotherapy — 5; 5; 5; 5 mg BID
Adult Malignant Fibrous Histiocytoma of Bone · Desmoid Tumor · Endometrial Cancer
Primary: Overall Objective Response — 1; 21; 26 participants
Urothelial Bladder Cancer · Triple-negative Breast Cancer · Pancreatic Ductal Adenocarcinoma
Primary: Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase — 18.8; 8.3; 0.0 Percentage of Patients
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Patients Tolerating Re-escalated Dose of Sorafenib for 28 Days Without Dose Interruption or De-escalation for Toxicity — 11 Participants
Solid Tumor
Primary: Number of Grade 3 or 4 Adverse Events, Highest Occurrence Per Participant — 1; 0; 0; 0 Adverse events
Locally Advanced Solid Tumor · Metastatic Solid Tumor · Breast Cancer
Primary: Number of Subjects With Dose Limiting Toxicities (DLT) — 0; 0; 0; 0 subjects
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Endometrial Adenocarcinomas · Neuroendocrine Tumors · Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
Primary: Maximum Tolerated Dose (MTD) — 50; 50; 5.0; 5.0 DOX mg/m2 PM01183 mg FD
Locally Advanced Pancreatic Adenocarcinoma
Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants
Pancreatic Cancer
Primary: One Year Survival Rate — 0.502 proportion of patients
Metastatic Carcinoma in the Adrenal Cortex · Stage III Adrenal Cortex Carcinoma AJCC v8 · Stage IV Adrenal Cortex Carcinoma AJCC v8
Primary: Progression-free Survival (PFS) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria — 72.2 precentage of participants
Non-small Cell Lung Cancer
Primary: Local Failure Free Survival — 9.4; 9.9 months
Solid Cancers
Primary: Time to Reach Maximum Observed Plasma Concentration (Tmax) at Steady-State for Both Total and Unbound GDC-0449 — 24; 72; 15; 74 hours
Tumors
Primary: Non-progression Rate (NPR) at 18 Weeks — 26.8; 44.4; 29.6; 40.0 percentage of participants
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Advanced Unresectable or Metastatic Solid Malignancy
Primary: Confirmed Objective Response Rate (ORR) Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Response…
Advanced Cancer
Primary: Urinary and Fecal Excretion of LY2603618 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 72.2; 11.0 percentage of total dose
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 1; 0; 0; 0 Participants